JAMA Surg:3D打印导航模板定位肺小结节的准确性

2019-01-05 xiangting MedSci原创

使用3D打印导航模板定位周围肺小结节的有效性和安全性并不差于CT引导法,并显著简化了定位手术和减少了患者的辐射暴露。

由于视频辅助胸腔镜手术中结节识别的困难性,肺小结节的定位存在挑战。使用三维(3-D)打印技术,研究人员最近创建了一个导航模板用于辅助经皮肺结节的定位;然而,该模板的有效性和安全性尚未得到评估。

这项研究旨在评估3D打印导航模板用于指导周围肺小结节定位有效性和安全性的非劣效性。

这是一项非劣效性随机临床试验,于2016年10月至2017年10月在中国上海肺科医院进行,比较了模板引导方法vs常规计算机断层扫描(CT)引导方法对肺结节定位的安全性和精确性。共招募了213名患有周围肺小结节(<2cm)的手术候选者进行CT或模板引导的肺结节定位。进行了意向治疗分析。干预内容为经皮肺结节定位。

主要结局是肺结节定位的准确性(定位偏差),次要结局是手术持续时间、放射剂量和并发症发生率。

200例患者按1:1比例随机分为模板引导组和CT引导组,大多数为女性(147 vs 53),体重指数范围为15.4-37.3,平均(SD)结节大小为9.7(2.9)mm,目标结节外缘与胸膜之间的平均距离为7.8(范围,0.0-43.9)mm。共有190例患者接受了CT或模板引导的肺结节定位及随后的手术。这些患者中,模板引导组和CT引导组的定位偏差没有显著差异(平均值[SD],8.7[6.9] vs 9.6[5.8] mm; P= .36)。模板引导组的平均(SD)手术持续时间为7.4(3.2)分钟,CT引导组为9.5(3.6)分钟(P<.001)。模板引导组的平均(SD)辐射剂量为229(65)mGy×cm,CT引导组为313(84)mGy×cm(P<.001)。

使用3D打印导航模板定位周围肺小结节的有效性和安全性并不差于CT引导法,并显著简化了定位手术和减少了患者的辐射暴露。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1905952, encodeId=1f2c190595280, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Mar 17 15:24:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994363, encodeId=ff7b1994363e0, content=<a href='/topic/show?id=359a4e09482' target=_blank style='color:#2F92EE;'>#小结节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47094, encryptionId=359a4e09482, topicName=小结节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=734374, createdName=gjsgj, createdTime=Fri Jan 25 10:24:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336092, encodeId=3b7c133609291, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Mon Jan 07 08:24:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357279, encodeId=199535e279d6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Jan 05 22:03:22 CST 2019, time=2019-01-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1905952, encodeId=1f2c190595280, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Mar 17 15:24:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994363, encodeId=ff7b1994363e0, content=<a href='/topic/show?id=359a4e09482' target=_blank style='color:#2F92EE;'>#小结节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47094, encryptionId=359a4e09482, topicName=小结节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=734374, createdName=gjsgj, createdTime=Fri Jan 25 10:24:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336092, encodeId=3b7c133609291, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Mon Jan 07 08:24:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357279, encodeId=199535e279d6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Jan 05 22:03:22 CST 2019, time=2019-01-05, status=1, ipAttribution=)]
    2019-01-25 gjsgj
  3. [GetPortalCommentsPageByObjectIdResponse(id=1905952, encodeId=1f2c190595280, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Mar 17 15:24:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994363, encodeId=ff7b1994363e0, content=<a href='/topic/show?id=359a4e09482' target=_blank style='color:#2F92EE;'>#小结节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47094, encryptionId=359a4e09482, topicName=小结节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=734374, createdName=gjsgj, createdTime=Fri Jan 25 10:24:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336092, encodeId=3b7c133609291, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Mon Jan 07 08:24:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357279, encodeId=199535e279d6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Jan 05 22:03:22 CST 2019, time=2019-01-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1905952, encodeId=1f2c190595280, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Mar 17 15:24:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994363, encodeId=ff7b1994363e0, content=<a href='/topic/show?id=359a4e09482' target=_blank style='color:#2F92EE;'>#小结节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47094, encryptionId=359a4e09482, topicName=小结节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=734374, createdName=gjsgj, createdTime=Fri Jan 25 10:24:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336092, encodeId=3b7c133609291, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Mon Jan 07 08:24:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357279, encodeId=199535e279d6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Jan 05 22:03:22 CST 2019, time=2019-01-05, status=1, ipAttribution=)]
    2019-01-05 医者仁心5538

    学习了

    0

相关资讯

Cell Rep:一箭双雕!乳腺癌药物将肺癌组织缩小66.7%!

乳腺癌和肺癌这两种看似八杆子打不着的两种肿瘤或许在发病机制上有着不为人知的相似性。我们在很久以前就知道乳腺癌中有一种类型是由于EGFR基因突变导致,但其实肺癌类型中也有一种具有相似的EGFR基因突变。

PLoS Med:深度学习在肺癌预测中的应用

这项研究结果提供了证据表明,深度学习网络可用于基于NSCLC患者标准治疗CT影像的死亡风险分层。

肺癌转移致脑膜癌病1例

患者,男性,61岁,因“间断头晕,伴恶心、呕吐半月。”入院,患者4年前确诊为右肺中叶腺癌。

益方生物与贝达合作开发肺癌创新药D-0316

今天,益方生物科技(上海)有限公司(以下简称“益方生物”)宣布,与贝达药业股份有限公司(以下简称 “贝达药业”)签订《合作协议》,由益方生物转让D-0316项目中国权益(包括中国大陆、香港和台湾)给贝达药业,并由贝达药业独家在约定区域内进行D-0316产品的开发及商业化。今天,益方生物科技(上海)有限公司宣布,与贝达药业股份有限公司签订《合作协议》,由益方生物转让D-0316项目中国权益(包括中

NEJM:转移性鳞状非小细胞肺癌一线治疗 免疫治疗+化疗生存期更长

继肿瘤靶向治疗之后,近几年免疫治疗大放异彩。对于转移性鳞状非小细胞肺癌(NSCLC),帕博利珠单抗(对于肿瘤细胞表达程序死亡配体1(PD-L1)≥50%的患者)几乎已成为与化疗齐驾并驱的一线治疗。2018年11月,发表在权威杂志《N Engl J Med》的一项研究再次显示,对于转移性鳞状NSCLC患者,与单纯化疗相比,帕博利珠单抗联合化疗一线治疗可带来更多生存获益。

BMJ:循环高敏C反应蛋白浓度与肺癌风险

由此可见,循环hsCRP浓度较高的既往和当前吸烟者总体肺癌风险较高。循环hsCRP浓度与肺腺癌的风险无关。循环hsCRP浓度可能是肺癌的预诊标志,而不是因果危险因素。